Compare SGMT & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SGMT | CPSS |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.2M | 201.5M |
| IPO Year | 2023 | 1992 |
| Metric | SGMT | CPSS |
|---|---|---|
| Price | $5.21 | $8.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | ★ 800.4K | 19.6K |
| Earning Date | 03-11-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.80 |
| Revenue | N/A | ★ $196,531,000.00 |
| Revenue This Year | N/A | $139.62 |
| Revenue Next Year | $125.00 | $10.58 |
| P/E Ratio | ★ N/A | $10.97 |
| Revenue Growth | N/A | ★ 6.67 |
| 52 Week Low | $1.73 | $6.67 |
| 52 Week High | $11.41 | $11.67 |
| Indicator | SGMT | CPSS |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 45.78 |
| Support Level | $5.31 | $8.47 |
| Resistance Level | $5.74 | $9.20 |
| Average True Range (ATR) | 0.52 | 0.31 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 8.70 | 52.17 |
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.